Merck is one of the largest pharmaceutical companies in the world. The company provides leading healthcare solutions to improve human and animal wellbeing around the world.
The treatment Merck has developed is an oral pill, called Mavenclad, which is used to treat highly active relapsing forms of multiple sclerosis in adults and has now been approved by European regulators.
The European Commission’s approval allows Merck to market Mavenclad in the EU’s 28 member countries.
Mavenclad is a short-course oral pill that is taken in two treatment courses, twelve months apart and works by gradually reducing the numbers of certain B-cells and T-cells.
The Phase III CLARITY trial was a 2-year trial that compared Mavenclad to a placebo. The results of the study showed that there was a reduction in the relapse rate of 58% with the lower dose and 55% with the higher dose. The trial also showed that Mavenclad harnessed the disease for 4 years but there was no need to continue with the treatment in years 3 and 4.
Multiple Sclerosis affects more than 700,000 people across Europe and has no cure to date. New treatment options will significantly help improve the quality of life of people living with active relapsing MS.
Anne Winslow, President of the European Multiple Sclerosis Platform
I like this website it’s a master piece! Glad I observed this ohttps://69v.topn google.Raise your business
Can you be more specific about the content of your article? After reading it, I still have some doubts. Hope you can help me.
Your article helped me a lot, is there any more related content? Thanks!
Your point of view caught my eye and was very interesting. Thanks. I have a question for you.
Thanks for sharing. I read many of your blog posts, cool, your blog is very good.
Your point of view caught my eye and was very interesting. Thanks. I have a question for you.
Thank you for your sharing. I am worried that I lack creative ideas. It is your article that makes me full of hope. Thank you. But, I have a question, can you help me?
Thanks for sharing. I read many of your blog posts, cool, your blog is very good.
I don’t think the title of your article matches the content lol. Just kidding, mainly because I had some doubts after reading the article.
Your point of view caught my eye and was very interesting. Thanks. I have a question for you.
Thanks for sharing. I read many of your blog posts, cool, your blog is very good.
Can you be more specific about the content of your article? After reading it, I still have some doubts. Hope you can help me.
Thanks for sharing. I read many of your blog posts, cool, your blog is very good.
Your article helped me a lot, is there any more related content? Thanks!